AI-based Clinical Trials
AI-based Clinical Trials Market by Component (Services, Software), Function (Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening), Phase, Technology, Application, End-user - Global Forecast 2024-2030
360iResearch Analyst
Want to know more about the ai-based clinical trials market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[197 Pages Report] The AI-based Clinical Trials Market size was estimated at USD 6.52 billion in 2023 and expected to reach USD 7.73 billion in 2024, at a CAGR 18.79% to reach USD 21.79 billion by 2030.

AI-based Clinical Trials Market
To learn more about this report, request a free PDF copy
AI-based clinical trials refer to the integration of artificial intelligence (AI) technologies into the design, conduct, and analysis of clinical trial data. AI algorithms have the capacity to rapidly explore large datasets, identify patterns, and make predictions that can streamline trial processes, enhance data quality, and optimize patient selection and outcomes. These trials can lead to the more efficient development of drugs, treatments, and medical devices, potentially reducing the time and cost associated with introducing new therapies. The increasing volume of biomedical data and the need for personalized medicine are significant drivers of AI-based clinical trials. The ability of the technology to process complex datasets can lead to more targeted, effective treatments. Additionally, AI usage can drive down costs and increase trial efficiency by automating tasks, including patient recruitment and data entry. Limitations include concerns regarding data privacy and security and the need for significant investment in AI technology and infrastructure. In addition, regulatory barriers pose limitations for the adoption of AI in clinical settings. AI propels the adoption of AI, and results in improved predictive analytics in patient outcomes, enhances the potential for discovering novel drug combinations, and offers the ability to monitor trials in real-time. The advent of AI is expected to democratize clinical trials by enabling remote monitoring and participation, broadening the scope and diversity of trial subjects, and the applicability of study results.
Market Dynamics

The market dynamics represent an ever-changing landscape of the AI-based Clinical Trials Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Need for artificial Intelligence which helps in boosting and improving clinical trials
    • Rising needs to reduce healthcare costs and declining hardware costs
    • Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
  • Market Restraints
    • Lack of personal involvement leading to a rise in unemployment rates
    • Possibility of a defective diagnosis
  • Market Opportunities
    • Technological advancements and innovations in AI-based clinical trials
    • Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
  • Market Challenges
    • Concerns associated with the adoption of EHR interoperability
Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the AI-based Clinical Trials Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the AI-based Clinical Trials Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the AI-based Clinical Trials Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the AI-based Clinical Trials Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the AI-based Clinical Trials Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the AI-based Clinical Trials Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the AI-based Clinical Trials Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the AI-based Clinical Trials Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the AI-based Clinical Trials Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the AI-based Clinical Trials Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI-based Clinical Trials Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI-based Clinical Trials Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI-based Clinical Trials Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the AI-based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aiforia Technologies Oyj, Antidote Technologies, Inc., Ardigen S.A., Avantor, Inc., BioAge Labs, BioSymetrics Inc., Deep 6 AI Inc., Envisagenics, Euretos Services BV, Exscientia PLC, GNS Healthcare, Google LLC by Alphabet Inc., Innoplexus AG, InSilico Medicine, Intel Corporation, International Business Machines Corporation, Koninklijke Philips N.V., Median Technologies, Nuritas Limited, Pharmaceutical Pipeline Enhancement Strategies, LLC, Saama Technologies, Inc., Symplr Software LLC,, Inc. by ZS Associates, Inc., and Unlearn.AI, Inc..

AI-based Clinical Trials Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the AI-based Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Services
    • Software
  • Function
    • Adverse Event Detection
    • Data Collection & Analysis
    • Patient Recruitment & Screening
    • Predictive Modeling
    • Trial Design & Optimization
  • Phase
    • Phase-I
    • Phase-II
    • Phase-III
  • Technology
    • Machine Learning
    • Natural Language Processing
  • Application
    • Cardiovascular Diseases
    • Infectious Diseases
    • Metabolic Diseases
    • Neurological Diseases
    • Oncology
  • End-user
    • Academic & Research Institutes
    • Contract Research Organization
    • Hospitals
    • Pharmaceutical & Biopharmaceutical Companies

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the AI-based Clinical Trials Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. AI-based Clinical Trials Market, by Component
  7. AI-based Clinical Trials Market, by Function
  8. AI-based Clinical Trials Market, by Phase
  9. AI-based Clinical Trials Market, by Technology
  10. AI-based Clinical Trials Market, by Application
  11. AI-based Clinical Trials Market, by End-user
  12. Americas AI-based Clinical Trials Market
  13. Asia-Pacific AI-based Clinical Trials Market
  14. Europe, Middle East & Africa AI-based Clinical Trials Market
  15. Competitive Landscape
  16. Competitive Portfolio
  17. List of Figures [Total: 28]
  18. List of Tables [Total: 562]
  19. List of Companies Mentioned [Total: 25]
How AI-based Clinical Trials are Changing the Medical Industry
January 7, 2024
How AI-based Clinical Trials are Changing the Medical Industry
Clinical trials are an essential part of the medical industry. The trials help in identifying new medical treatments, verifying their effectiveness, and ensuring their safety. However, clinical trials are time-consuming and costly, which poses huge challenges for researchers who are looking for new treatment options. Fortunately, the integration of artificial intelligence or AI in clinical trials is changing the game. AI-based clinical trials are helping researchers in boosting and improving outcomes. In this article, we shall explore how AI-based clinical trials are changing the medical industry.

Efficiency in Clinical Trials:

AI technology can help speed up the clinical trial process by automating some of the tasks needed for the trial. This can be done through the processing of large amounts of data with speed and accuracy. The analysis of data by AI systems is much more efficient than human analysis, and as a result, researchers can save time and focus on other critical tasks.

Faster Patient Recruitment:

Patient recruitment is a significant challenge in clinical trials. AI systems can help accelerate patient recruitment in clinical trials. By using machine learning algorithms, AI-based solutions can identify the ideal participants for clinical trials. This saves researchers time and money in recruiting the right candidates for their studies.

A More Accurate Diagnosis:

In some clinical trials, it's important to have an accurate diagnosis before the study can proceed. AI systems can provide a more accurate diagnosis by analyzing medical data, including a patient's medical history, genetic makeup, and existing health conditions. By providing more accurate diagnoses, researchers can better estimate the effectiveness of their study.

Improved Adherence to Protocols:

Adherence to study protocols is key to the success of clinical trials. Traditional methods of monitoring patients are prone to error as they are reliant on the patients following protocols accurately. With AI-based solutions, researchers can more accurately track patients' adherence to protocols. The AI systems record data in real-time, and this can help researchers make necessary adjustments before it's too late.

Reduced Cost of Clinical Trials:

Conducting clinical trials can be very expensive, with costs sometimes running into millions of dollars. By automating some of the tasks, AI systems can significantly reduce the cost of clinical trials. Improved patient recruitment and adherence to protocols can also help reduce costs while improving outcomes. As a result, smaller organizations, like startups, can now afford to conduct clinical trials.

AI-based clinical trials are changing the way clinical trials are conducted, and they have the potential to revolutionize and improve the medical industry. The integration of AI technology in clinical trials has resulted in increased efficiency, accurate diagnosis, reduced costs, and improved adherence to protocols. Furthermore, AI systems can help recruit the right patients, which saves time and improves clinical outcomes. As we move towards a future of healthcare that puts patients at the center, AI-based clinical trials will play a critical role in identifying new treatments that can improve millions of lives.

Frequently Asked Questions
  1. How big is the AI-based Clinical Trials Market?
    Ans. The Global AI-based Clinical Trials Market size was estimated at USD 6.52 billion in 2023 and expected to reach USD 7.73 billion in 2024.
  2. What is the AI-based Clinical Trials Market growth?
    Ans. The Global AI-based Clinical Trials Market to grow USD 21.79 billion by 2030, at a CAGR of 18.79%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.